Alpine Immune Sciences announced it released the results of a preclinical study of immuno-oncology molecules derived from the company’s variant immunoglobulin (Ig) domain (vIgD) platform.
Alpine Immune Sciences (NASDAQ:ALPN) announced it released the results of a preclinical study of immuno-oncology molecules derived from the company’s variant immunoglobulin (Ig) domain (vIgD) platform.
As quoted in the press release:
Alpine scientists fused these novel molecules with trastuzumab with the goal of activating T cells against HER2-positive tumors in the tumor microenvironment. Results showed these trastuzumab-ICOSL “V-mAbs” promoted T cell proliferation and cytokine secretion and enhanced killing of tumor cells. The data were presented in a poster session, titled “Treatment: Novel Targets and Targeted Agents (abstract # P1-09-10),” during the 40th Annual San Antonio Breast Cancer Symposium (SABCS).
“These preclinical data clearly indicate that the V-mAb format for our unique vIgD platform can yield novel HER2-targeted, T cell-activating immunotherapies,” said Stanford Peng, M.D., Ph.D., Executive Vice President of Research and Development and Chief Medical Officer of Alpine. “With these findings, we are encouraged that the V-mAb format more broadly will be able to enable target- or tumor-specific immune modulation by our vIgDs for this and many other therapeutic applications.”